C4 Therapeutics
CCCC
CCCC
100 hedge funds and large institutions have $94.1M invested in C4 Therapeutics in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 36 increasing their positions, 35 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
20% less capital invested
Capital invested by funds: $117M → $94.1M (-$23.3M)
56% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 36
Holders
100
Holding in Top 10
–
Calls
$154K
Puts
$6K
Top Buyers
| 1 | +$5.45M | |
| 2 | +$4.08M | |
| 3 | +$2.75M | |
| 4 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$2.09M |
| 5 |
D.E. Shaw & Co
New York
|
+$894K |
Top Sellers
| 1 | -$16.7M | |
| 2 | -$4.43M | |
| 3 | -$1.7M | |
| 4 |
Nuveen Asset Management
Chicago,
Illinois
|
-$1.12M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.11M |